These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38780840)

  • 1. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
    Li X; Wu D; Tang J; Wu Y
    J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.
    Zhang J; Lv PY; Zhao X; Liu ML; Qiu LP; Yang ZZ; Sun SJ; Zhang GQ
    BMC Cancer; 2024 Aug; 24(1):967. PubMed ID: 39112947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of treatment outcome between first-line combination immunotherapy (anti-PD-L1 or anti-PD1) with or without chemotherapy and chemotherapy alone in advanced non-small cell lung cancer patients in tertiary care hospital.
    Naratornsirakul D; Chewaskulyong B; Kongkarnka S; Oranratnachai S
    Cancer Med; 2024 Jul; 13(14):e70007. PubMed ID: 39030820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
    Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
    Wasilewski D; Onken J; Höricke P; Bukatz J; Murad S; Früh A; Shaked Z; Misch M; Kühl A; Klein O; Ehret F; Kaul D; Radbruch H; Capper D; Vajkoczy P; Horst D; Frost N; Bischoff P
    J Neurooncol; 2024 Mar; 167(1):155-167. PubMed ID: 38358406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
    Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
    Vallejo J; Singh H; Larkins E; Drezner N; Ricciuti B; Mishra-Kalyani P; Tang S; Beaver JA; Awad MM
    Oncologist; 2024 May; 29(5):422-430. PubMed ID: 38349736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
    BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer].
    Chen Q; Li Y; Zhang W; Yang S; Wang C; Guo Q; Shi W
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):605-612. PubMed ID: 34455735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.
    Man J; Millican J; Mulvey A; Gebski V; Hui R
    JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34084999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.